ObjectivesWe characterized one strain of S.salivarius 24SMB, isolated from healthy children, as a potential oral probiotic due to the followingcharacteristics: i) safety for the host, ii) potent capacity of adhesion to HEp-2 cells and iii) excellent inhibitory activity againstS.pneumonia and S.pyogenes by bacterioncin production.Aim of the study was to evaluate safety of S.salivarius 24SMB and its ability to colonize and persist in the upper respiratory tract whenadministered as nasal spray formulation.MethodsThe study enrolled 17 patients: the formulation was given for 3 days after azithromycin treatment and the presence of S. salivarius 24SMB was determined after 2/4/ 24 h, and 7 days from nasal spray administration plating nasal swabs for each time onto MSA.ResultsOur results demonstrated: i) the absence of adverse effects for all subjects enrolled, and ii) the capability of S. salivarius 24 SMB topersist in rhinopharynx tissue in 50% of subjects after 6 days from the last dose of the formulation (105 CFU/mL). The presence ofour stain was determined by molecular identification, antagonism tests to evaluate BLIS production and RAPD-PCR to distinguish S.salivarius 24 SMB’s genotype from other S.salivarius strains. The nasal spray was well tolerated in all patients.ConclusionAll these characteristics make this strain suitable for use in bateriotherapy. This strain is currently under clinical evaluation in a randomizeddouble blind trial for the prevention and/or treatment of chronic otitis media in pediatric age patients.

Application of bacteriotherapy in human rhinopharynx

SANTAGATI, Maria Carmela;LA MANTIA, Ignazio;STEFANI, Stefania
2014

Abstract

ObjectivesWe characterized one strain of S.salivarius 24SMB, isolated from healthy children, as a potential oral probiotic due to the followingcharacteristics: i) safety for the host, ii) potent capacity of adhesion to HEp-2 cells and iii) excellent inhibitory activity againstS.pneumonia and S.pyogenes by bacterioncin production.Aim of the study was to evaluate safety of S.salivarius 24SMB and its ability to colonize and persist in the upper respiratory tract whenadministered as nasal spray formulation.MethodsThe study enrolled 17 patients: the formulation was given for 3 days after azithromycin treatment and the presence of S. salivarius 24SMB was determined after 2/4/ 24 h, and 7 days from nasal spray administration plating nasal swabs for each time onto MSA.ResultsOur results demonstrated: i) the absence of adverse effects for all subjects enrolled, and ii) the capability of S. salivarius 24 SMB topersist in rhinopharynx tissue in 50% of subjects after 6 days from the last dose of the formulation (105 CFU/mL). The presence ofour stain was determined by molecular identification, antagonism tests to evaluate BLIS production and RAPD-PCR to distinguish S.salivarius 24 SMB’s genotype from other S.salivarius strains. The nasal spray was well tolerated in all patients.ConclusionAll these characteristics make this strain suitable for use in bateriotherapy. This strain is currently under clinical evaluation in a randomizeddouble blind trial for the prevention and/or treatment of chronic otitis media in pediatric age patients.
Streptococcus salivarius; bacteriotherapy; chronic otitis media in pediatric age patients
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/103727
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact